Senseonics Holdings

Senseonics Holdings, Inc. engages in the design, development, and commercialization of an implantable continuous glucose monitoring system for people with diabetes. Its primary product is the brand Eversense, a glucose monitoring device which includes sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Senseonics achieves FDA milestone with Eversense 365, focuses on growth

Senseonics had a pivotal quarter with FDA approval of Eversense 365, driving positive feedback and strong adoption.
Financially, the company reported Q3 net revenue of $4.3 million with a gross loss of $4.1 million, focusing on cost reduction.
Efforts to reduce operating expenses and extend cash runway aim to address financial challenges and enhance stability.
With opportunities to accelerate sales, improve diabetes management, and expand market reach, Senseonics is poised for growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Senseonics Holdings, Inc. is a medical technology company, which engages in the development and manufacture of glucose monitoring products. Its primary product is the brand Eversense CGM (continuous glucose monitoring) including sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

Senseonics Holdings, Inc.'s (SENS) CEO Tim Goodnow on Q4 2020 Results - Earnings Call Transcript

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter and full year ended December 31, 2020. Recent Highlights & Accomplishments: Generated fourth quarter 2020 revenue of $3.9 million primarily driven by orders to support the European installe

Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming virtual H.C. Wainwright Global Life Sciences Conference. Management is scheduled to participate and hold one-on-one meetings Tuesday, March 9, 2021. A presentation webcast will be available

Senseonics to Participate in the H.C. Wainwright Global Life Sciences Conference

The stock price of Senseonics Holdings Inc (NYSEAMERICAN: SENS) is trading up over 8%. This is why it happened.

SENS Stock Price Increases Over 8% Pre-Market: Why It Happened

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its fourth quarter and full year 2020 financial results after market close on Thursday, March 4, 2021. Management will hold a conference call to review the company's fourth quarter and full year 2020 p

Senseonics Holdings, Inc. Schedules Fourth Quarter and Full Year 2020 Earnings Release and Conference Call for March 4, 2021 at 4:30 p.m. Eastern Time

The stock price of Senseonics Holdings Inc (NYSEAMERICAN: SENS) increased by 26.92% today. This is why it happened.

SENS Stock Price Increased 26.92%: Why It Happened

GERMANTOWN, Md,--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming virtual SVB Leerink Global Healthcare Conference. Management is scheduled to present Thursday, February 25, 2021 at 12:00 pm ET. Interested parties may access a live and recorded webcast of

Senseonics to Participate in the SVB Leerink Global Healthcare Conference

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that Ascensia Diabetes Care (Ascensia) has commenced sales and marketing activities for the Eversense® XL CGM system in key European markets as of today, as part of their strategic partnership announced in August, 2020. “Today

Senseonics Announces Initiation of European Commercial Efforts by Partner Ascensia Diabetes Care

Clovis Oncology

Dynavax Technologies

Lannett Company

Cenntro Electric Group

OPKO Health

Precigen

TherapeuticsMD

United Microelectronics

VBI Vaccines

The movement of retail traders against hedge funds has caused several stocks to spike. Many of the top movers have been stocks that have a high percentage of their floated shares short, causing what's known as a short squeeze.

10 Short Squeeze Candidates Under $10

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS) (“Senseonics” or the “Company”), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the closing on January 26, 2021, of its previously announced public underwritten offering of 59,740,259 shares of common stock of the Company, including the exercise in full by the underwriter

Senseonics Holdings Announces Closing of $115.0 Million Bought Deal Offering of Common Stock and Full Exercise of the Option to Purchase Additional Shares

The stock price of Senseonics Holdings Inc (NYSEAMERICAN: SENS) has increased by over 25% pre-market. This is why it happened.

SENS Stock Price Increases Over 25% Pre-Market: Why It Happened

Senseonics Holdings (SENS) has moved higher as of late, but there could definitely be trouble on the horizon for this company.

Senseonics (SENS) Enters Overbought Territory

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS) (“Senseonics” or the “Company”), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that, due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 51,948,052 shares of common stock of the Compan

Senseonics Holdings Increases Previously Announced Bought Deal Offering of Common Stock to $100.0 Million

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS) (“Senseonics” or the “Company”), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co. under which the underwriter has agreed to purchase on a firm commitment basis 25,974,026 shares of common stock

Senseonics Holdings Announces $50.0 Million Bought Deal Offering of Common Stock

Senseonics Holdings, Inc (AMEX: SENS) shares spiked nearly 87% in the regular and after-hour sessions on Tuesday. What Happened: The medical technology company said EmblemHealth, one of the largest not-for-profit health insurers in the United States, is now providing coverage for Senseonics' Eversense continuous glucose monitoring (CGM) system for people with diabetes.

Why Senseonics Shares Spiked 87% Today

The specialist in glucose monitoring is helping people with diabetes manage their health.

Why Senseonics Stock Skyrocketed 80% Today

The stock price of Senseonics Holdings Inc (NYSEAMERICAN: SENS) is trading at over 75% today. This is why it happened.

SENS Stock Price Increases Over 75%: Why It Happened

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, announced today that EmblemHealth is now providing coverage for the Eversense® CGM System, effective immediately. This recent coverage decision adds to the growing number of payers who are writing Eversense into their CGM coverage policies, as

Senseonics Announces a Positive Coverage Decision for Eversense CGM from EmblemHealth

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it has entered into securities purchase agreements with several healthcare-focused and other institutional investors to purchase 40,000,000 shares of its common stock in a registered direct offering at a purchase price of

Senseonics Holdings Announces $50.0 Million Registered Direct Offering of Common Stock

Senseonics Holdings (SENS) stock is on the rise Friday with heavy trading despite a lack of news concerning the pharmaceutical company. The post SENS Stock Alert: 10 Things to Know Before Investing in Senseonics Holdings appeared first on InvestorPlace.

SENS Stock Alert: 10 Things to Know Before Investing in Senseonics Holdings

Investors need to pay close attention to Senseonics Holdings (SENS) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Senseonics Holdings (SENS) Stock?

The stock price of Senseonics Holdings Inc (NYSEAMERICAN: SENS) increased by 145.95% this past month. This is why it happened.

SENS Stock Price Increased 145.95% This Past Month: Why It Happened

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, announced today financial and operational business updates. Recent Developments Fourth quarter 2020 net revenue is expected to be approximately $3.5 million, increased from the prior expectation of approximately $2.5 million Received communic

Senseonics Announces Business Update

BIOLASE

Jaguar Health

Tonix Pharmaceuticals Hld

This article is going to explain what penny stocks are and discuss four penny stocks under $1 to watch as small-cap stocks continue a hot streak this winter. First thing's first, what are penny stocks?

4 Hot Penny Stocks Trading Under $1 That Need To Be On Your Watchlist

Senseonics Holdings (SENS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

News for Senseonics Holdings Stock (SENS)